4591.T) reported positive results from its domestic Phase II clinical trial of umedaptanib pegol, an">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from RIBOMIC Inc. was processed by Pulse News Wire on March 10, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

RIBOMIC Announces Positive Phase II Clinical Trial Results for Achondroplasia Treatment

TOKYO, Mar 10 (Pulse News Wire) – RIBOMIC Inc. (4591.T) reported positive results from its domestic Phase II clinical trial of umedaptanib pegol, an anti-FGF2 aptamer, for treating achondroplasia in p

View all 4591.T disclosures →

Share this disclosure: Share on X Share on LinkedIn